ubenimex has been researched along with Myelodysplastic Syndromes in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arima, T; Chyuma, Y; Hanada, S; Nishimata, H; Saito, T; Utsunomiya, A | 1 |
| Saito, Y; Usuka, Y | 1 |
| Im, T; Nakao, H; Oohira, H; Ota, K; Sannomiya, Y; Sasaki, A; Tatsumi, N; Yasui, Y | 1 |
| Fukutani, H; Kimura, I; Miura, Y; Mizoguchi, H; Naoe, T; Ohno, R; Ohshima, T; Omine, M; Saito, H; Tomonaga, M | 1 |
| Saito, Y; Uzuka, Y | 1 |
1 trial(s) available for ubenimex and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Treatment of myelodysplastic syndromes with orally administered N-(2S, 3R)-3-amino-2-hydroxy-4-phenylbutyryl-L-leucine (ubenimex).
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Aminopeptidases; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Child; Female; Humans; Leucine; Leukemia; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies | 1991 |
4 other study(ies) available for ubenimex and Myelodysplastic Syndromes
| Article | Year |
|---|---|
[Hemolytic anemia complicated with Behçet's disease and myelodysplastic syndrome].
Topics: Adult; Anemia, Hemolytic; Behcet Syndrome; Female; Humans; Leucine; Myelodysplastic Syndromes | 1992 |
Bestatin treatment of myelodysplastic syndromes and chronic myelogenous leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Busulfan; Drug Therapy, Combination; Female; Humans; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelodysplastic Syndromes | 1991 |
Effects of ubenimex, a biological response modifier, on myelodysplastic syndrome and chronic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Female; Humans; Immunologic Factors; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelodysplastic Syndromes | 1991 |
Bestatin treatment of myelodysplastic syndromes (MDS) and the effects of bestatin on hematopoiesis in MDS.
Topics: Aged; Aged, 80 and over; Bone Marrow; Cells, Cultured; Colony-Forming Units Assay; Female; Hematopoiesis; Humans; Leucine; Male; Middle Aged; Myelodysplastic Syndromes; T-Lymphocytes | 1990 |